The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Novartis; Pfizer
Ranee Mehra
No relevant relationships to disclose
Dong-Wan Kim
Consultant or Advisory Role - Novartis
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Laura Quan Man Chow
Research Funding - Novartis
D. Ross Camidge
Consultant or Advisory Role - Novartis
Daniel Shao-Weng Tan
Research Funding - Novartis
Johan F. Vansteenkiste
No relevant relationships to disclose
Sunil Sharma
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Tommaso De Pas
No relevant relationships to disclose
Juergen Wolf
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Ryohei Katayama
No relevant relationships to disclose
Yi-Yang Yvonne Lau
Employment or Leadership Position - Novartis
Meredith Goldwasser
Employment or Leadership Position - Novartis
Anthony Boral
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey A. Engelman
Consultant or Advisory Role - Novartis
Research Funding - Novartis